Editor’s note: This is a developing news story. Please check back soon for updates.
A second phase 3 pivotal clinical trial investigating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia met its primary and key secondary endpoints, according to a press release from Opus Genetics.
“Presbyopia is one of the most common ocular conditions. Many patients are seeking a noninvasive treatment that doesn’t compromise distance vision or nighttime visual function,” George Magrath, MD, CEO of Opus Genetics, told Healio. “The results from VEGA-3 are